Fassarar Adabi
Wani bincike da aka yi kwanan nan kan aiwatar da gwajin maganin pharmacogenetic (PGx) a Italiya, wanda aka buga a cikin Mujallar Turai ta Halittar Dan Adam, ya bayyana yadda ake rarraba ayyukan gwajin PGx, aikace-aikacen fasaha, aiwatar da asibiti, bambance-bambancen yanki, da matsalolin da ake fuskanta a yanzu a Italiya, yana ba da tushen shaida don haɓaka ilimin pharmacogenetics a Italiya da sauran ƙasashen Turai.
I. Bayani da Manufa
A halin yanzu, amfani da fasahar PGx a asibiti a Italiya ya rabu, ba tare da tsarin haɗin kai na ƙasa da kuma fahimtar juna ba. Domin fayyace yanayin gwajin magunguna na ƙasar, ƙungiyar binciken ta gudanar da wani bincike a duk faɗin ƙasar daga Janairu zuwa Oktoba 2025. Manyan manufofin sune:
-Don zana taswirar rarrabawa da sabis na dakunan gwaje-gwajen magunguna a Italiya;
-Don fayyace gwajin hanyoyin aiki, bangarorin kwayoyin halitta, hanyoyin fasaha, da ƙa'idodin fassara;
-Don bayyana bambance-bambancen yankuna da shingayen aiwatarwa, tare da samar da tallafin bayanai don daidaita daidaiton ƙasa.
II. Mahimman Sakamako
Halaye na asali na dakunan gwaje-gwaje
Siffar cibiyoyi: Cibiyoyi 49 ne suka shiga, wanda kashi 82% daga cikinsu cibiyoyin gwamnati ne, yayin da kashi 18% kawai masu zaman kansu ne.
-Sashen da ke gudanar da ayyuka: Sashen kwayoyin halittar likitanci sun fi kowanne girma (39%), sai kuma sashen ilimin cututtuka da sinadarai na asibiti (18%), sai kuma sashen ilimin magunguna na asibiti (12%).
Gwajin aikace-aikace da manufofin kwayoyin halitta
Yanayin aikace-aikacen asali:Gwajin PGx a Italiya ya fi mayar da hankali kan cutar kansa. Kashi 94% (dakunan gwaje-gwaje 46) sun yi gwajin kwayar halittar dihydropyrimidine dehydrogenase (DPYD) da ta shafi amfani da fluoropyrimidine, kuma kashi 84% (dakunan gwaje-gwaje 41) sun yi gwajin kwayar halittar uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) da ta shafi amfani da irinotecan.
Wasu gwaje-gwaje:Dakunan gwaje-gwaje da ke gudanar da gwaje-gwaje don gano kwayoyin halittar da ke da alaƙa da azathioprine, clopidogrel, warfarin, da sauransu (TPMT, CYP2C19, CYP2C9, VKORC1, da sauransu) ba kasafai ake samun su ba.
Fasaha da bin ƙa'ida daidai gwargwado
Dabarun gwaji: Kashi 100% na gwaje-gwajen DPYD da kashi 97% na UGT1A1 gwaje-gwaje ne kafin magani; CYP2C19 da HLA B galibi gwaje-gwaje ne na rigakafi; gwajin CYP2D6 galibi yana amsawa ne, an yi shi ne bayan an sami sakamako mara kyau.
Hanyoyin fasaha:Hanyar PCR ta ainihin lokaci ita ce dabarar da aka fi amfani da ita; An fi amfani da NGS don gano kwayar halittar HLA B; daga cikin cibiyoyin da suka bayar da rahoton sakamako, dakin gwaje-gwaje guda ɗaya ne kawai ya yi amfani da cikakken tsarin exome (WES).
Daidaiton bin ƙa'ida:Yawancin dakunan gwaje-gwaje sun bi jagororin Ƙungiyar Magunguna ta Italiya/Ƙungiyar Likitoci ta Italiya (SIF/AIOM) da kuma jagororin Ƙungiyar Ayyukan Magunguna ta Clinical Pharmacogenetics (CPIC)/Ƙungiyar Aiki ta Dutch Pharmacogenetics (DPWG).
Fassarar sakamako da shawara
Sa hannun rahoto:Kashi 65% na rahotannin gwaji kwararru ne suka sanya hannu a kansu, yayin da 31% kuma kwararru a fannin cututtuka/kwayoyin halitta suka sanya hannu a kansu.
Fassarar asibiti: Kashi 90% na dakunan gwaje-gwaje sun bayar da fassarar magani, kashi 73% sun nuna haɗarin guba/rashin inganci, amma kashi 24% ne kawai suka bayar da takamaiman shawarwari kan yadda za a sha magani.
Shawarwari kan fannin harhada magunguna:Kashi 29% ne kawai na dakunan gwaje-gwaje ke bayar da ayyukan ba da shawara kan magunguna, kuma waɗannan kusan sassan ilimin magunguna ne kawai ke ba da su - sassan ilimin halittar jini da ilimin cututtuka ba su bayar da su sosai ba.
Yarjejeniyar da aka sanar:Kashi 73% na dakunan gwaje-gwaje sun aiwatar da takamaiman sharuɗɗan izini ko na gabaɗaya game da ilimin magunguna.
Rarraba yanki:An fi mai da hankali kan ayyukan gwaji a arewacin Italiya. Daga cikin dakunan gwaje-gwaje masu girman gwaji na shekara-shekara sama da 200, 23 suna arewa, 4 a tsakiya, da 6 a kudu da tsibirai - rarraba wuraren gwaji ba daidai ba ne a yankuna.
Girman gwaji:Kashi 69% na dakunan gwaje-gwaje suna da adadin gwaje-gwajen da suka wuce 200 a kowace shekara, kashi 19% kuma suna da 100,200.
Tsarin biyan kuɗi:Daga cikin dakunan gwaje-gwaje da aka yi bincike a kansu, kashi 73% sun sami cikakken kuɗin da aka biya daga Tsarin Lafiya na Ƙasa (NHS), kashi 22% na kuɗin da aka biya, da kuma kashi 4% babu kuɗin da aka biya. Dokokin biyan kuɗi na yanki ba su daidaita ba. A halin yanzu, Italiya ba ta da takamaiman lambar biyan kuɗi/biya don gwajin magunguna, wanda ke haifar da rudani sosai a aiwatarwa a yankuna daban-daban.
III. Tattaunawa da Kammalawa Masu Muhimmanci
Matsayi na gaba a fannin ilimin cutar kansa (oncology)– Gwajin DPYD da UGT1A1 ya yaɗu saboda haɓaka jagororin Hukumar Magunguna ta Turai (EMA) da Hukumar Magunguna ta Italiya (AIFA). Duk da haka, amfani da gwajin magunguna a fannonin da ba na ciwon daji ba bai isa ba sosai.
Fasaha da fassarar da ba ta iri ɗaya ba– Babu wani mizani ɗaya da aka haɗa don gwajin allunan gwaji, reagents, kayan aikin bioinformatics, ko ka'idojin fassara, wanda ke haifar da rashin daidaiton sakamako.
Rashin isasshen haɗin gwiwa tsakanin fannoni daban-daban– Rashin shigar kwararrun masana magunguna da kuma rashin isassun hanyoyin kula da magunguna na asibiti.
Babban rashin daidaito na yanki– Albarkatun gwajin PGx galibi suna da yawa a cibiyoyin kiwon lafiya na arewa, tare da ƙarancin albarkatu a yankunan tsakiya da kudu - gibin hannun jari.
Tallafin manufofi masu rauni– Italiya ba ta da tsarin ƙasa ɗaya tilo don gwajin ƙwayoyin cuta, wanda hakan ya haifar da rashin cikakken tsarin biyan kuɗi, tsari, horo, da sauransu.
Takaitaccen Bayani
Wannan binciken shine kimantawa ta farko a duk fadin kasar game da matsayin aiwatar da maganin gargajiya a Italiya. Ya tabbatar da cewa an fara aiwatar da maganin gargajiya a Italiya a fannin ilimin halittar jiki, amma gabaɗaya an raba shi, ba a daidaita shi ba, ba shi da daidaito a yanki, kuma ba shi da alaƙa da fannoni daban-daban. Saboda haka, kafa tsarin haɗin gwiwa na ƙasa, haɗa ƙa'idodin fasaha da fassarar, da inganta manufofi da horo su ne buƙatun da Italiya ke buƙata a nan gaba don cimma daidaiton amfani da gwajin maganin gargajiya, wanda ke ba da muhimmiyar ma'ana ga sauran ƙasashen Turai.
Gwajin Macro & Micro'sCikakken Maganin Magungunan Magungunan Kai-tsaye
-Mai Sauƙi: Loda samfurin tare da bututun asali, gudu ɗaya mai maɓalli, sarrafa samfuri-zuwa-sakamako, haɗin kai mara matsala tare da LIS/HIS.
-Mai SauriSakamakon yana samuwa cikin kimanin awa 1 don dukkan tsarin, wanda ke jagorantar daidai tsarin magunguna na musamman.
-Mai sassauci: Tare da dandamalin HWTS AIO800, gwajin PGx ba ya iyakancewa ta hanyar ƙuntatawa na wurin aiki - sassauƙa da kuma amfani da damammaki daban-daban.
-Cikakke: Matrix mai wadataccen samfura wanda ya shafi cututtukan zuciya da jijiyoyin jini, cututtukan tabin hankali, maganin oncology, haihuwa, ilimin mata da haihuwa, da sauran fannoni.
-Daidaitawa:Mai nazarin ƙara ƙarfin sinadarin nucleic acid mai cikakken sarrafa kansa HWTS AIO800 da tsarin PCR na lokaci-lokaci na gargajiya.
Karin Bayani:Mai alaƙaCututtukaes, Magunguna Masu Alaƙa, da Manufofin Gwajin Halitta Masu Daidaito
Lokacin Saƙo: Mayu-11-2026